Randal Scott Sells 10,000 BridgeBio Pharma Shares for $754,600

Director Randal Scott of BridgeBio Pharma, Inc. (NASDAQ: BBIO) executed a significant stock sale on February 17, 2024. He sold 10,000 shares at an average price of $75.46, amounting to a total transaction value of $754,600. Following this sale, Scott now holds 11,589 shares valued at approximately $874,505.94, reflecting a 46.32% reduction in his stake in the company. This transaction was reported in a filing with the U.S. Securities and Exchange Commission (SEC).

BridgeBio Pharma’s stock opened at $70.72 on Friday, showing a decline of 4.3%. The company has experienced volatility over the past year, with a low of $28.33 and a high of $84.94. The firm’s market capitalization stands at $13.63 billion, with a price-to-earnings ratio of -16.92 and a beta of 1.13.

Market Reactions and Analyst Ratings

The sale has sparked varied reactions among analysts and brokerages. Raymond James Financial set a target price of $89.00 and categorized the stock as “outperform” in a report dated February 12, 2024. Meanwhile, Barclays initiated coverage on the stock with an “overweight” rating. Evercore reaffirmed an “outperform” rating, while Weiss Ratings issued a “sell (d-)” rating on January 21, 2024.

Recent upgrades from Truist Financial raised their price target from $80.00 to $86.00, maintaining a “buy” rating. Overall, 22 analysts have rated the stock as a Buy, with one giving it a Sell rating, resulting in a consensus rating of “Moderate Buy” and an average target price of $82.05.

Insider Activity and Institutional Investments

The recent insider selling, including Scott’s transaction, has created some concern among investors. On the same day, the CFO sold 13,600 shares valued at approximately $1.02 million, alongside other officer sales. Such concentrated disposals often influence market sentiment negatively, leading to increased scrutiny of the stock’s performance.

Institutional investors hold a significant portion of BridgeBio Pharma, with ownership at 99.85%. Recent filings reveal that Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake valued at $25,000, while Aster Capital Management DIFC Ltd. and others made similar strategic investments during the third quarter.

As of now, the company is preparing for its upcoming earnings report for Q4 2025, along with a conference call scheduled for February 24, 2024. This event could introduce volatility as investors evaluate the financial results and cash flow details.

Company Overview

Founded in 2015 and headquartered in Palo Alto, California, BridgeBio Pharma focuses on developing transformative medicines for genetic diseases and cancers. The company employs an integrated model that encompasses target identification, preclinical research, clinical development, and commercialization. Its diverse pipeline includes various therapeutic modalities such as small molecules, biologics, and genetic therapies.

In summary, Randal Scott’s recent sale of shares has drawn attention in the financial community, coinciding with a mix of analyst upgrades and concerns over insider transactions. Investors will be closely watching upcoming earnings and market movements as BridgeBio Pharma continues to navigate its developmental landscape.